Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.

"Potential Conflicts of Interest CH, JW, and GK are employees of and have stock in F. Hoffmann‐La Roche, Ltd, which manufactures gantenerumab one of the drugs tested in this study, and CH also has a patent planned for gantenerumab. KCH, MM, and RY are employees of and have stock in Eli Lilly and Company, which manufactures solanezumab the other drug tested in this study. SEB, NCF, JH, CJM received consulting fees and JL speaker fees from F. Hoffman‐La Roche, Ltd. EM reports receiving personal honorarium for Continuing Medical Education activities for Eli Lilly and Company. SPS is the Gantenerumab Project Arm Leader for the DIAN‐TU‐001 study and receives consulting fees from F. Hoffmann‐La Roche, Ltd. and Eli Lilly and Company. TLSB reports receiving radiopharmaceuticals and technology from Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company. DBC is Medical Director for the DIAN‐TU‐001 study and has received consulting fees from F. Hoffmann‐La Roche, Ltd./Genentech. The former Department Head of Neurology at Washington University, Dr. David Holtzman, is an inventor on patents for solanezumab which was tested in this study. If solanezumab is approved as a treatment for Alzheimer's disease or dominantly inherited Alzheimer's disease, Washington University and Dr. Holtzman will receive part of the net sales of solanezumab from Eli Lilly and Company."

"Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers U01AG042791, R01AG046179, R01AG053267. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The research for the DIAN‐TU‐001 trial, solanezumab and gantenerumab drug arms, was also supported by the Alzheimer's Association, Eli Lilly and Company, F. Hoffmann‐La Roche Ltd., Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly and Company), GHR Foundation, an anonymous organization, FNIH and Accelerating Medicines Partnership, Cogstate, and Signant. The DIAN‐TU has received funding from the DIAN‐TU Pharma Consortium. N.J‐M. and J.J.L‐G. gratefully acknowledge supports from the Alzheimer's Association Research Fellowship to promote diversity (AARFD‐20‐681815 and AARFD‐21‐851415, respectively). We acknowledge the altruism of the participants and their families and contributions of the DIAN, DIAN Expanded Registry, and DIAN‐TU research and support staff at each of the participating sites (see DIAN‐TU Study Team) for their contributions to this study."